(Q43865208)
Statements
1 reference
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis (English)
1 reference
1 reference
Kenneth H Kim
1 reference
Kimberly E Resnick
1 reference
David M O'Malley
1 reference
J Michael Straughn
1 reference
7 March 2011
1 reference
1 reference
29
1 reference
10
1 reference
1247-1251
1 reference
Identifiers
1 reference
1 reference